Close Menu
Home » NCCN Mentions Prolaris, Oncotype DX in Updated Prostate Cancer Guidelines

NCCN Mentions Prolaris, Oncotype DX in Updated Prostate Cancer Guidelines

Oct 27, 2014
|
staff reporter

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has included two molecular diagnostics – Myriad Genetics' Prolaris and Genomic Health's Oncotype DX Prostate Cancer – in its most recent guidelines for the disease, noting that these two assays "appear further along in development and clinical use" than other options on the market.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Gene Editing for the Gold

Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.

Variant Linked to Heart Failure Risk

A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.

A Different Future

In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."

Nature Examines Lifespans, Fast and Accurate Method for Long-Read Assembly, More

In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.